LuciAcal — Acalabrutinib 100 mg, 60 pcs, Lucius

LuciAcal — Acalabrutinib 100 mg Capsules, 60 Capsules

Product code: 491

29055₴ 31603₴ -8% On order · from 10 days

Analogues

1
Active ingredient
Dosage
100 mg
Dosage form Capsules
Capsules per pack 60

LuciAcal is a modern, highly selective second-generation targeted antineoplastic agent belonging to the Bruton's tyrosine kinase (BTK) inhibitor class, indicated for the treatment of B-cell hematologic and lymphoid malignancies. The active pharmaceutical ingredient is acalabrutinib at a strength of 100 mg supplied as hard oral capsules (Acalabrutinib Capsules 100 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Acalabrutinib is a selective small-molecule covalent inhibitor of Bruton's tyrosine kinase (BTK), an essential signaling molecule of the B-cell antigen receptor (BCR) pathway. By forming a covalent bond with a cysteine residue (Cys481) in the BTK active site, acalabrutinib irreversibly inhibits enzymatic activity, blocking downstream signaling required for malignant B-lymphocyte activation, proliferation, migration, and survival. Compared to first-generation BTK inhibitors (such as ibrutinib), acalabrutinib exhibits markedly superior kinase selectivity with minimal off-target inhibition (EGFR, ITK, TEC), resulting in significantly lower incidence of cardiovascular adverse events (atrial fibrillation) and major bleeding.

Supplied in a bottle/carton containing 60 capsules of 100 mg (providing a full 30-day supply at the standard twice-daily regimen). Intended for oral administration under the supervision of a qualified hematologist or oncologist.

Key Clinical Features and Advantages of LuciAcal 100 mg:

  • ✅ Second-Generation Selectivity: Potent, targeted BTK inhibition with minimal off-target kinase activity.
  • ✅ Enhanced Cardiovascular Safety Profile: Substantially lower rates of atrial fibrillation and hypertension compared to first-generation BTK inhibitors.
  • ✅ Convenient Oral Administration: Taken orally twice daily, enabling effective outpatient management without hospital stays.
  • ✅ Efficacy in High-Risk Subtypes: Strong clinical activity in chronic lymphocytic leukemia (including 17p deletion cases) and relapsed/refractory mantle cell lymphoma.
  • ✅ Full Monthly Supply: 60 capsules (100 mg) cover a complete 30-day maintenance treatment cycle.

LuciAcal is supplied as hard capsules for oral administration.

Qualitative and Quantitative Composition per Capsule:

  • Active Ingredient: Acalabrutinib — 100 mg.
  • Excipients: Microcrystalline cellulose, colloidal anhydrous silica, sodium starch glycolate, magnesium stearate. Capsule shell: gelatin, titanium dioxide (E171), approved pharmaceutical colorants.

Packaging and Presentation: Hard gelatin capsules containing white to off-white powder or granules. 60 capsules in a tamper-evident HDPE bottle enclosed in an outer carton with prescribing information, displaying LuciAcal (Acalabrutinib Capsules 100 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Acalabrutinib is a selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK). BTK signaling is critical for B-cell proliferation, trafficking, chemotaxis, and adhesion. Acalabrutinib and its active metabolite (ACP-5862) bind covalently to a cysteine residue in the BTK active site, leading to sustained enzymatic inactivation and suppression of malignant B-cell clonal expansion.

Pharmacokinetics:

  • Absorption: Rapidly absorbed following oral administration. Median time to peak plasma concentration (Tmax) is 0.75 hours for acalabrutinib and 1.0 hour for its active metabolite ACP-5862. Mean absolute bioavailability is approximately 25%.
  • Distribution: Human plasma protein binding is 97.5% for acalabrutinib and 98.6% for ACP-5862. Mean steady-state volume of distribution is approximately 34 L.
  • Metabolism: Predominantly metabolized in the liver via cytochrome P450 3A4 (CYP3A4) to its major active metabolite ACP-5862, which is approximately half as potent as acalabrutinib toward BTK inhibition but circulates at higher plasma exposure.
  • Elimination: Excreted primarily via feces (approximately 84% of dose, mostly as metabolites) and urine (approximately 12%). Mean terminal elimination half-life (T1/2) is 1 to 2 hours for acalabrutinib and approximately 7 hours for ACP-5862.

LuciAcal is indicated in adult patients for:

  • Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL): As monotherapy or in combination with obinutuzumab for treatment-naïve adult patients with CLL/SLL, and as monotherapy for patients who have received at least one prior therapy.
  • Mantle Cell Lymphoma (MCL): Treatment of adult patients with relapsed or refractory mantle cell lymphoma who have received at least one prior line of therapy.

LuciAcal is administered orally twice daily approximately 12 hours apart, with or without food. Capsules must be swallowed whole with water; do not open, break, or chew capsules.

Dosing Regimen:
The recommended standard dose is 100 mg (1 capsule) every 12 hours (total daily dose of 200 mg). Continue treatment until disease progression or unacceptable toxicity.

Missed Dose Instructions: If a dose is missed by less than 3 hours, take it immediately. If missed by more than 3 hours, skip the missed dose and resume the regular dosing schedule at the next planned time.

Administration of LuciAcal is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to acalabrutinib or any excipient.
  • Pregnancy and Lactation: Contraindicated during pregnancy and breastfeeding.
  • Severe Hepatic Impairment: Severe liver dysfunction (Child-Pugh Class C).
  • Pediatric Population: Safety and efficacy in patients under 18 years of age have not been established.

Acalabrutinib is metabolized by CYP3A4, and the capsule formulation requires gastric acidity for optimal dissolution:

  • Gastric Acid-Reducing Agents (Capsule Formulation): Co-administration with proton pump inhibitors (omeprazole, pantoprazole) significantly reduces acalabrutinib absorption and must be avoided. Separate dosing from H2-receptor antagonists (famotidine) or antacids by at least 2 hours.
  • Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): Substantially increase acalabrutinib plasma exposure and toxicity risks. Avoid concurrent use.
  • Strong CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Markedly decrease acalabrutinib concentrations, compromising efficacy.
  • Anticoagulants and Antiplatelet Agents (warfarin, clopidogrel, aspirin): Concurrent administration elevates bleeding risk; close clinical monitoring is warranted.

Pregnancy:
LuciAcal is contraindicated during pregnancy based on animal studies demonstrating embryo-fetal toxicity and developmental harm. Females of reproductive potential must use effective contraception during treatment and for at least 2 days (or up to 1 month per clinical guidance) following the last dose.

Lactation:
Excretion into human breast milk is unknown. Breastfeeding should be discontinued during therapy and for at least 2 weeks after the final dose.

The most frequent and clinically significant adverse reactions include:

  • Hematologic Toxicity: Neutropenia, anemia, thrombocytopenia, lymphopenia. Monthly complete blood counts are recommended.
  • Hemorrhage: Contusion, petechiae, epistaxis; less commonly, major hemorrhage (consider withholding therapy 3 to 7 days pre- and post-surgery).
  • Infections: Upper respiratory tract infections, sinusitis, pneumonia, urinary tract infections, hepatitis B or herpesvirus reactivation.
  • Nervous System: Headache (very common, typically mild and transient during initial weeks of therapy, manageable with standard analgesics), dizziness.
  • Gastrointestinal Tract: Diarrhea, nausea, abdominal pain, constipation, vomiting.
  • Musculoskeletal & General Disorders: Musculoskeletal pain, arthralgia, fatigue, skin rash.
  • Cardiovascular System: Atrial fibrillation or flutter (substantially lower incidence than ibrutinib, though cardiac monitoring is advised if symptoms arise).

Symptoms:
Clinical data regarding acalabrutinib overdose are limited; exaggerated adverse events such as severe headache, nausea, diarrhea, thrombocytopenia, and bleeding are anticipated.

Treatment:
No specific antidote exists. Patients should be closely monitored and provided supportive and symptomatic care. Hemodialysis is unlikely to significantly clear acalabrutinib due to extensive plasma protein binding.

Storage Requirements for LuciAcal 100 mg:

  • 🌡️ Temperature Range: Store in original tightly closed container in a dry place protected from light at 15 °C to 30 °C.
  • 💧 Moisture Protection: Do not remove the desiccant canister from the bottle; close cap tightly after each use.
  • 👶 Safety Precautions: Keep strictly out of reach of children.
  • ⏳ Shelf Life: Stated on outer carton and bottle label. Do not use past expiration date. Prescription-only oncology/hematology medicine.

To verify authenticity of genuine LuciAcal (100 mg) manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Acalabrutinib Capsules 100 mg, and 60 Capsules count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across both the outer box and inner HDPE bottle.
  • ✅ Tamper-Evident Seal: Intact induction foil seal under the bottle cap and official product insert inside the carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 14.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00